Tom 15, Nr 3 (2018)
Farmakoterapia chorób układu krążenia
Opublikowany online: 2018-12-11
Wyświetlenia strony
570
Wyświetlenia/pobrania artykułu
1206
Wpływ terapii skojarzonej opartej na ezetimibie i statynie na metabolizm cholesterolu w świetle aktualnej wiedzy medycznej
Choroby Serca i Naczyń 2018;15(3):135-145.
Streszczenie
Artykuł stanowi próbę syntezy poglądów dotyczących fizjologii krążenia cholesterolu, a także roli zaburzeń lipidowych i ich wpływu na ryzyko sercowo-naczyniowe w różnych populacjach pacjentów. Jednocześnie w pracy opisano mechanizmy i sposoby terapeutycznej ingerencji w metabolizm lipoprotein osocza ze szczególnym uwzględnieniem w tym procesie skojarzonego wpływu statyn i ezetimibu. W ostatniej części artykułu zweryfikowano zasadność zastosowania powyższego schematu hipolipemizującego na podstawie dowodów uzyskanych w wieloośrodkowych randomizowanych badaniach klinicznych.
Słowa kluczowe: statyna i ezetimibterapia skojarzona
Referencje
- Konturek S. Czynności wątroby. In: Traczyk ZW, Trzebski A, Godlewski A. ed. Fizjologia człowieka z elementami fizjologii stosowanej i klinicznej. Wydawnictwo Lekarskie PZWL, Warszawa 2007: 806.
- Murray RK, Granner DK, Mayes PA. Harper’s Biochemistry. 23ED. Prentice-Hall International Inc., Londyn 1993: 197–273.
- Feingold KR, Grunfeld C. Introduction to Lipids and Lipoproteins. In: De Groot LJ, Beck-Peccoz P, Chrousos G. ed. Endotext. MDText.com, Inc., South Dartmouth (MA) 2000.
- Burchardt P, Wiktorowicz K, Goździcka-Józefiak A, et al. Disturbances in mitochondrial biosynthesis of acetyl-CoA and their role in the prevention of ischemic heart disease. Kardiol Pol. 2008; 66(11): 1215–1220.
- Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 1983; 52: 223–261.
- Wadhera RK, Steen DL, Khan I, et al. A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. J Clin Lipidol. 2016; 10(3): 472–489.
- Dawber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease: the Framingham Study presented at a Joint Session of the Epidemiology, Health Officers, Medical Care, and Statistics Sections of the American Public Health Association, at the Seventy-eighth Annual Meeting in St. Louis, November 3, 1950. Am J Public Health Nations Health. 1951; 41(3): 279–281.
- Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364(9438): 937–952.
- Catapano AL, Graham I, De Backer G, et al. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37(39): 2999–3058.
- Bardini G, Giorda CB, Pontiroli AE, et al. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol. 2010; 9: 20.
- Battaggia A, Donzelli A, Font M, et al. Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2015; 10(4): e0124587.
- Pirillo A, Catapano AL, Norata GD. Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases. Curr Med Chem. 2016; 23(10): 983–999.
- Miura Si, Saku K. Ezetimibe, a selective inhibitor of the transport of cholesterol. Intern Med. 2008; 47(13): 1165–1170.
- Saeed A, Ballantyne CM. Bempedoic Acid (ETC-1002): A Current Review. Cardiol Clin. 2018; 36(2): 257–264.
- Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol. 2014; 54: 273–293.
- Oi K, Komori H. Escape phenomenon with pravastatin during long-term treatment of patients with hyperlipidemia associated with diabetes mellitus. Curr Therapeutic Res. 1998; 59(2): 130–138.
- Reckless JPD, Henry P, Pomykaj T, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract. 2008; 62(4): 539–554.
- Bays HE, Davidson MH, Massaad R, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011; 108(4): 523–530.
- Ballantyne CM, Weiss R, Moccetti T, et al. EXPLORER Study Investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007; 99(5): 673–680.
- Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008; 52(25): 2198–2205.
- Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376(18): 1713–1722.
- Drygas W, Niklas AA, Piwońska A, et al. Multi-centre National Population Health Examination Survey (WOBASZ II study): assumptions, methods, and implementation. Kardiol Pol. 2016; 74(7): 681–690.
- Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005; 80(5): 587–595.
- Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract. 2009; 63(4): 547–559.
- Robinson JG, Ballantyne CM, Grundy SM, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009; 103(12): 1694–1702.
- McCormack T, Harvey P, Gaunt R, et al. IN-PRACTICE study. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract. 2010; 64(8): 1052–1061.
- Ballantyne CM, Hoogeveen RC, Raya JL, et al. GRAVITY Study Investigators. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study. Atherosclerosis. 2014; 232(1): 86–93.
- Patel AY, Pillarisetti J, Marr J, et al. Ezetimibe in combination with a statin does not reduce all-cause mortality. J Clin Med Res. 2013; 5(4): 275–280.
- Kastelein JJP, Akdim F, Stroes ESG, et al. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008; 358(14): 1431–1443.
- Simon T, Boutouyrie P, Gompel A, et al. CASHMERE investigators. Rationale, design and methods of the CASHMERE study. Fundam Clin Pharmacol. 2004; 18(1): 131–138.
- Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol. 2009; 49(7): 838–847.
- Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010; 160(5): 785–794.e10.
- Rossebø A, Pedersen T, Allen C, et al. Design and Baseline Characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study. Am J Cardiol. 2007; 99(7): 970–973.
- Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372(25): 2387–2397.
